Scans for upcoming FDA and European regulatory catalysts, including newly announced events and companies not already on the calendar.
LIVE CATALYST FEED
Upcoming pharma catalysts, ranked by research materiality.
Official-source monitoring of upcoming pharma catalysts. Catalyst Sensitivity ranks relative issuer/event materiality — not a price target, approval probability or recommendation.
—Upcoming
—Analyzed
180dHorizon
RECENT CHANGES
LAST 7 DAYS✓
Checking for material catalyst changes…Official regulatory and company sources
HOW IT WORKS
From regulatory signal to research-priority view.
HOW IT WORKS
From regulatory signal to research-priority view.
The Observer combines source verification, company mapping and a rules-based scoring model. It is designed to help prioritize independent research — not predict a regulatory decision or tell users what to trade.
Matches the company, drug and event to primary or official sources where possible. Unclear matches stay pending instead of being treated as confirmed.
Evaluates event shock, company exposure and company size to estimate the catalyst's relative materiality to the company.
Re-checks the pipeline for new dates, regulatory developments and other material changes, then surfaces them in Recent Changes.
How to read the scores
Catalyst Sensitivity
A 0–100 model score for relative issuer sensitivity to a catalyst based on event shock, company exposure and company size. It does not predict direction, approval probability, a percentage price move or investment return.
Event Shock
Measures how consequential and binary the underlying catalyst is. A major regulatory decision generally carries more shock than a routine update.
Company Exposure
Estimates how economically important the drug or program may be to the company. Greater concentration can increase the event's materiality to the issuer.
Company Size
Provides relative scale context. A single catalyst can matter differently to a small biotech than to a diversified large pharmaceutical company.
Evidence Quality
Confidence is driven mainly by source quality, then the amount of supporting evidence, freshness and data completeness. Regulator pages and SEC filings carry the most weight, followed by company IR; secondary articles carry less.
Outcome State
Future binary regulatory events remain unresolved until an actual decision or clearly directional development occurs. Scheduled dates are not treated as bullish or bearish.
Catalyst Sensitivity scaleMODEL SCORE · RESEARCH INDICATOR
Limited0–24
Lower modeled issuer sensitivity to this specific catalyst.
Moderate25–44
Moderate modeled sensitivity, with meaningful but non-dominant company exposure.
Strong45–74
High modeled sensitivity because the event may materially alter expectations for an important program.
Major75–100
Very high modeled sensitivity, typically where event shock and company exposure are both substantial.
Cards can span more than one band — for example, Strong → Major means the model range crosses both categories. The scale is a research-prioritization indicator only; it does not predict price direction, price magnitude, regulatory outcome, approval probability or actual return.
Loading live catalysts...
FEEDBACK
Help make The Observer better.
Found a wrong date, missing catalyst, confusing score or feature you want? Send it directly to us.
Used The Observer?
Review on Trustpilot →
We’re still small, so genuine feedback matters. If The Observer has been useful, leave an honest review on Trustpilot — good or bad.